Successful Treatment of Mucous Membrane Pemphigoid with Dupilumab: A Case Report

Authors

  • Zhiyi Wang First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, P.R. China
  • Xiaojing Liu First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, P.R. China
  • Jing Ni First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, P.R. China
  • Yushuo Qi First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, P.R. China
  • Zhiqi Song First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, P.R. China
  • Yongjun Piao First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, P.R. China

DOI:

https://doi.org/10.2340/actadv.v104.40162

Keywords:

Mucous membrane pemphigoid, dupilumab, Biologics, pemphigoid

Abstract

Abstract is missing (Short communication)

Downloads

Download data is not yet available.

References

Du G, Patzelt S, van Beek N, Schmidt E. Mucous membrane pemphigoid. Autoimmun Rev 2022; 21: 103036.

https://doi.org/10.1016/j.autrev.2022.103036

Rashid H, Lamberts A, Borradori L, Alberti-Violetti S, Barry RJ, Caproni M, et al. European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part I. J Eur Acad Dermatol Venereol 2021; 35: 1750-1764.

https://doi.org/10.1111/jdv.17397

Olbrich H, Sadik CD, Schmidt E. Autoimmune blistering diseases: promising agents in clinical trials. Expert Opin Investig Drugs 2023; 32: 615-623.

https://doi.org/10.1080/13543784.2023.2242778

Russo R, Cozzani E, Gasparini G, Parodi A. Targeting interleukin 4 receptor α: a new approach to the treatment of cutaneous autoimmune bullous diseases? Dermatol Ther 2020; 33: e13190.

https://doi.org/10.1111/dth.13190

Rashid H, Meijer JM, Bolling MC, Diercks GFH, Pas HH, Horváth B. Insights into clinical and diagnostic findings as well as treatment responses in patients with mucous membrane pemphigoid: a retrospective cohort study. J Am Acad Dermatol 2022; 87: 48-55.

https://doi.org/10.1016/j.jaad.2021.11.061

Schmidt E, Rashid H, Marzano AV, Lamberts A, Di Zenzo G, Diercks GFH, et al. European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part II. J Eur Acad Dermatol Venereol 2021; 35: 1926-1948.

https://doi.org/10.1111/jdv.17395

Russo R, Capurro N, Cozzani E, Parodi A. Use of dupilumab in bullous pemphigoid: where are we now? J Clin Med 2022; 11: 3367.

https://doi.org/10.3390/jcm11123367

Raef HS, Elmariah SB. Successful treatment of Brunsting-Perry cicatricial pemphigoid with dupilumab. J Drugs Dermatol 2021; 20: 1113-1115.

Maloney NJ, Tegtmeyer K, Zhao J, Worswick S. Dupilumab in dermatology: potential for uses beyond atopic dermatitis. J Drugs Dermatol 2019; 18: S1545961619P1053X.

Downloads

Published

2024-08-26

How to Cite

Wang, Z., Liu, X., Ni, J., Qi, Y., Song, Z., & Piao, Y. (2024). Successful Treatment of Mucous Membrane Pemphigoid with Dupilumab: A Case Report. Acta Dermato-Venereologica, 104, adv40162. https://doi.org/10.2340/actadv.v104.40162